ClinicalTrials.gg
RecruitingNCT01109420Updated Nov 20, 2026

Clinical and Genetic Studies in Familial Non-medullary Thyroid Cancer

An observational study in Non-Medullary Thyroid Cancer, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Recruiting at 1 site in United States. Open to participants aged 7 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Observational

How we know

From the registry’s dates

  • Started Aug 2010; still recruiting 16 years 3 months later.
Updated Nov 9, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
7 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 283 studies in Thyroid Neoplasms with a site in United States — 53 open to participants now, 88 under way, 3 of them phase 3. Thyroid Neoplasms · United States.

Planned enrollment
16th of 47
500 · median 200
Started
2010
with 6 others
Observational
47 of 283
18 open now
Registered
79th of 283
by date
Lead sponsor
9 of 283
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 16th largest by planned enrollment of the 47 observational ones that give a count, is one of 7 that started in 2010, is one of 47 observational ones, and was the 79th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

53 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 7 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Thyroid Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Background:

- Researchers are studying types of thyroid cancer that seem to cluster in families. Non-medullary thyroid cancer accounts for the vast majority of all types of thyroid cancer, but little is known about possible genes that may cause the cancer. More research is needed to develop the best ways to screen for familial non-medullary thyroid cancer (FNMTC) so that it can be diagnosed and treated at an early stage.

Objectives:

  • To evaluate the natural history of FNMTC.
  • To determine the best screening strategy for FNMTC.
  • To identify genes that may indicate susceptibility to FNMTC.

Eligibility:

- Individuals at least 7 years of age who have two first-degree relatives (e.g., parents, children, siblings) who have or have had non-medullary thyroid cancer or a documented diagnosis of non-medullary thyroid cancer and one living relative with documented non-medullary thyroid cancer.

Design:

  • Participants will be evaluated by family history pedigree, physical examination, imaging (including possible neck ultrasound and radioactive iodine scans), and laboratory testing.
  • Participants who agree to have blood or other biological samples collected will be asked to enroll in an additional study to provide the appropriate samples and tissues.
  • After the initial study evaluation, participants who are not found to have a malignant thyroid tumor will be re-screened every year with non-invasive imaging studies. Participants who are found to have a malignant thyroid tumor will be informed of possible treatment options.
Read the detailed description

Study Description:

This is a prospective cohort study of individuals with or at risk for non-medullary thyroid cancer. Individuals will be studied over time within the context of their families in order to quantify prospective risks of cancers in family members, to establish the natural history of FNMTC, define the spectrum of diseases within the families, to identify precursor states, to try to assess the contribution of genetic and environmental components of risk, and to develop effective screening strategies.

Objectives:

  1. To evaluate the natural history of familial non-medullary thyroid cancer (FNMTC).
  2. To determine the best screening strategy for FNMTC.
  3. To identify susceptibility gene(s) for FNMTC.

Endpoints:

Not applicable

03

Conditions studied

  • Non-Medullary Thyroid Cancer

Browse trials for

Keywords

  • Hereditary Cancer
  • Susceptibility Gene(s) for Thyroid Cancer
  • Screening at Risk Family Members
  • Natural History
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
7 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

An individual with 2 first-degree relatives who have or have had non-medullary thyroid cancer or a documented diagnosis of non-medullary thyroid cancer and one living relative with documented non-medullary thyroid cancer (Note: as this is a familial study, subjects do not need to present with the disease) OR Any member of an affected family. (Note: for this study, an affected family is defined as a family having 2 or more 1st degree relatives with a documented diagnosis of FNMTC.)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be selected for this protocol based on either a clinical diagnosis of non-medullary thyroid cancer and the presence of one family member with the disease or the presence of 2 living family members with this disease. Patient selection for this protocol will not be based on gender, race, or ethnic background.

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Adults or minor (>= 7 years+), males and females.
  • An unaffected individual with >= 2 first-degree relatives who have or have had nonmedullary thyroid cancer

OR

-An affected individual with documented diagnosis of non-medullary thyroid cancer and >= one living relative with documented non-medullary thyroid cancer (Note: as this is a familial study, subjects do not need to present with the disease)

OR

  • Any member of an affected family. (Note: for this study, an affected family is defined as a family having 2 or more 1st degree relatives with a documented diagnosis of FNMTC.)
  • Adults must be able to understand and the willingness to sign the document.
  • Adults must be able to complete the family history questionnaire.

Exclusion criteria

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will not be allowed to enroll in this study:

-Subjects unwilling/unable to give .

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)

Groups and cohorts

  • 1/ Cohort 1

    Affected with non-medullary thyroid cancer

  • 2/ Cohort 2

    Non-affected members of families with non-medullary thyroid cancer

06

What researchers measure

Primary outcomes

  1. To evaluate the natural history of FNMTC

    Evaluation the natural history of FNMTC

    Time frame: end of study

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) · Contactccopr@nih.gov · 800-411-1222
08

References and documents

Publications

  • Ito Y, Kakudo K, Hirokawa M, Fukushima M, Yabuta T, Tomoda C, Inoue H, Kihara M, Higashiyama T, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A. Biological behavior and prognosis of familial papillary thyroid carcinoma. Surgery. 2009 Jan;145(1):100-5. doi: 10.1016/j.surg.2008.08.004. Epub 2008 Sep 21. PubMed 19081481 ↗
  • Vriens MR, Suh I, Moses W, Kebebew E. Clinical features and genetic predisposition to hereditary nonmedullary thyroid cancer. Thyroid. 2009 Dec;19(12):1343-9. doi: 10.1089/thy.2009.1607. PubMed 20001717 ↗
  • Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009 Aug 15;115(16):3801-7. doi: 10.1002/cncr.24416. PubMed 19598221 ↗
  • Chuki E, Behairy N, Auh S, Makarewicz A, Uttarkar Vikram CN, Kumari S, Veeraraghavan P, Cochran C, Gubbi S, Klubo-Gwiezdzinska J. Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients. Thyroid. 2025 Jun;35(6):642-651. doi: 10.1089/thy.2024.0588. Epub 2025 May 20. PubMed 40392709 ↗
  • Klubo-Gwiezdzinska J, Yang L, Merkel R, Patel D, Nilubol N, Merino MJ, Skarulis M, Sadowski SM, Kebebew E. Results of Screening in Familial Non-Medullary Thyroid Cancer. Thyroid. 2017 Aug;27(8):1017-1024. doi: 10.1089/thy.2016.0668. Epub 2017 Jul 19. PubMed 28657510 ↗

Individual participant data

Plan to share: No — Subject level data will be shared upon request after appropriate collaboration agreements are in place.

09

Timeline

7 registry updates since Sep 25, 2026

Started Aug 2010 (actual).

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2010
First posted
Apr 23, 2010
StartActual
Aug 12, 2010
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Criteria revised in 2 updates
What changed on Nov 5, 2026
Inclusion criteria
  • EditedAn unaffected individual with (Bullet)>= 2 first-degree relatives who have or have had nonmedullary thyroid cancer
  • Edited-An affected individual with documented diagnosis of non-medullary thyroid cancer and (Bullet)>= one living relative with documented non-medullary thyroid cancer (Note: as this is a familial study, subjects do not need to present with the disease)
What changed on Nov 9, 2026
Exclusion criteria
  • EditedAn individual who meets any of the following criteria will be not be allowed to enroll in this study:
across 2 updates, Nov 5, 2026 – Nov 9, 2026
Show all 7 updates
  1. Nov 20, 2026
    Minor edits only
    + 1 other change: description
  2. Nov 12, 2026
    Minor edits only
    + 1 other change: description
  3. Nov 9, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedAn individual who meets any of the following criteria will be not be allowed to enroll in this study:
    + 2 other changes: verification date and description
  4. Nov 5, 2026
    Eligibility 2 inclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAn unaffected individual with (Bullet)>= 2 first-degree relatives who have or have had nonmedullary thyroid cancer
    • Edited-An affected individual with documented diagnosis of non-medullary thyroid cancer and (Bullet)>= one living relative with documented non-medullary thyroid cancer (Note: as this is a familial study, subjects do not need to present with the disease)
    + 1 other change: description
  5. Oct 13, 2026
    Minor edits only
    + 1 other change: description
  6. Oct 8, 2026
    Minor edits only
    + 1 other change: description
  7. Oct 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01109420
Responsible party
Sponsor
First posted
Apr 23, 2010
Start date
Aug 12, 2010
Last update
Nov 20, 2026

Study contacts

Padmasree Veeraraghavan, R.N.
Contact
ncieobinquiry@mail.nih.gov
(301) 451-7710
Joanna Klubo-Gwiezdzinska, M.D.
Contact
joanna.klubo-gwiezdzinska@nih.gov
(301) 496-5052
Joanna Klubo-Gwiezdzinska, M.D.
principal investigator · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion